The Trial Never Ends, an article in Drug Development by Gus Gardner

For pharmaceutical companies, information is power. To gain that power, many drug companies use patient-reported outcomes (PROs) to measure the impact and effectiveness of their drugs during Phase 2 and Phase 3 clinical trials. The success they’ve experienced using PROs has prompted expansion of the way these tools are utilized. Drug developers have found that the information gathered can be used throughout the entire clinical trial continuum—and beyond.

View the full article to read more about the expanding role of patient reported outcome surveys.